August 2025
Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025
Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.
July 2025
Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.
Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’
Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025
Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer fromthe German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.
Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash
Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.
June 2025
Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.